EP1345898A2 — Teracyclic carbazole derivates and their use as spla2 inhibitors
Assigned to Eli Lilly and Co · Expires 2003-09-24 · 23y expired
What this patent protects
A novel class of tetracyclic compounds is disclosed represented by the formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug derivative thereof; wherein; A is independently C, or N; n is 1, 2 or 3; together with the use of such compounds for inhibiting sPLA2 med…
USPTO Abstract
A novel class of tetracyclic compounds is disclosed represented by the formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug derivative thereof; wherein; A is independently C, or N; n is 1, 2 or 3; together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
Drugs covered by this patent
- Vascepa (ICOSAPENT ETHYL) · Amarin Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.